131 related articles for article (PubMed ID: 37132126)
1. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.
Nebgen DR; Domchek SM; Kotsopoulos J; de Hullu JA; Crosbie EJ; Paramanandam VS; Brood-van Zanten MMA; Norquist BM; Guise T; Rozenberg S; Kurian AW; Pederson HJ; Yuksel N; Michaelson-Cohen R; Bober SL; da Silva Filho AL; Johansen N; Guidozzi F; Evans DG; Menon U; Kingsberg SA; Powell CB; Grandi G; Marchetti C; Jacobson M; Brennan DJ; Hickey M
BJOG; 2023 Nov; 130(12):1437-1450. PubMed ID: 37132126
[TBL] [Abstract][Full Text] [Related]
2. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
3. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
[TBL] [Abstract][Full Text] [Related]
4. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
5. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
6. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
[TBL] [Abstract][Full Text] [Related]
7. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
[TBL] [Abstract][Full Text] [Related]
9. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
[TBL] [Abstract][Full Text] [Related]
10. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant.
Zilski N; Speiser D; Bartley J; Roehle R; Blohmer JU; Keilholz U; Goerling U
J Sex Med; 2023 Dec; 21(1):33-39. PubMed ID: 37973412
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
13. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
14. What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.
Hickey M; Trainer A; Braat S; Davey MA; Krejany E; Wark J
BMJ Open; 2017 Nov; 7(11):e018758. PubMed ID: 29138210
[TBL] [Abstract][Full Text] [Related]
15. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
16. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
17. Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
Vermeulen RFM; van Beurden M; Gaarenstroom KN; Teunis T; Kieffer JM; Aaronson NK; Kenter GG; Korse CM
Climacteric; 2018 Dec; 21(6):574-580. PubMed ID: 30295077
[TBL] [Abstract][Full Text] [Related]
18. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
[TBL] [Abstract][Full Text] [Related]
19. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
[TBL] [Abstract][Full Text] [Related]
20. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Solsky I; Chen J; Rebbeck TR
Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
